The effect of 2,2-diamino-2,5 di(4-hydroxyphenyl)-4-oxo-5-thiouryl-(1,2,4) oxazolidine (Oxa.), a biological active compound on some blood parameters in laboratory mice


The 2,2-diamino-2,5 di(4-hydroxyphenyl)-4-oxo-5-thiouryl-(1,2,4) Oxazolidine (Oxa.) compound has a biological activity against Gram negative bacteria (E. coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853) and a Gram positive bacteria (Staphylococcus aureus ATCC 25923) reference strains, with no cytotoxicity on RBCs, and 11.7 gm/kg lethal dose. It is a bacteriostatic agent on bacterial protein synthesis was studied on some blood parameters in the laboratory mice Balb/C. In this study three groups of mice were used, one as a control and the others administrated 0.1 and 0.25 gm/kg, respectively, for a month. The results showed that there was insignificant decrease in the haemoglobin in the two administrated groups, and the lowest value was (10.06 g/100 ml) in the first group comparing with the control group which was (11.65 g/100ml), in addition to that, the result showed a significant increase in the total count of the white blood cells (WBCs) in the second administrated group (4.01x103//mm3) comparing with the control group (2.22x103/mm3), whereas no change was noticed on the first group, the basophile cells was increased (2%) in the second administrated group comparing with the control group (1.25%) and the first group which has (0.7%) basophile cells. The result showed also a significant increase in the lymphocyte cells (58%) in the first group comparing with the control (39.75%) and the second group (47.5%), the neutrophils showed a significant decrease in both first (17.25%) and second (27.75%) groups comparing with the control (34.25%), whereas no change was noticed in the eosinophils and the monocytes between the three groups.


  • Attassi K, Hershberger E, Alam R, Zervos MJ, (2002) Thrompocytopenia association with linezolid therapy. Cli. Infec. Dis. 34: 695-698.
  • Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ, (2003) Mechanisms for linezolid-induced anemia and thrombocytopenia. The Ann. Of Pharmacoth. 37: 517-520.
  • Birmingham MC, Rayer CR, Meagher AK, Flavin SM, Batts DH, Schentang JJ, (2003) Linezolid for the treatment of multidrug-resistant gram- positive infections: experience for a compassion ate- use program. Cli. Inf. Dis. 36: 159-168.
  • Brunner M, (2006) Synthetic studies towards sphingosine-related metabolites. (Thesis) Helsinki University of Technology, Department of Chemical Technology, Laboratory of Organic Chemistry. 52 pp.
  • Cammarata SK, Bermudez M, Golin V, (2000) Comparison of Linezolid versus Ceftriaxone / Cefpodoxime in the treatment of hospitalized community-acquired pneumonia. (Abstract). In: Abstracts of the International Congress on Infectious Diseases. Buenos Aires. Argentina. April 10-13-2000. Boston. MA: International Society for Infectious Diseases. 224.
  • Colca JR, McDonald WG, Waldon DJ, Thomasco LM, Gadwood RC, Lund EJ, Cavey GS, Mathews ER, Adams LD, Cecil ET, Pearson JD, Bock JH, Mott JE, Shinabarger DL, Xiong L, Mankin AS, (2003) Cross-linking in the living cell located the site of action of Oaxzolidinone antibiotics. Journal Biol. Chem. 278: 21972-21979.
  • Daly JS, Eliopoulos GM, Reiszr E, Moellering RC,(1988) Activity and mechanism of action of Dup 105 and Dup 721, new oxazolidinone antimicrobials. Journal of Antimicrob. Chemother. 21: 721- 730.
  • Daly JS, Eliopoulos GM, Willey S, Moellering RC, (1988) Mechanism of action and in vitro and in vivo activities of S- 6123, a new oxazolidinone compound. Antimicrob. Agents and Chemother. 32: 1341-1346.
  • Fines M, Leclereq R, (2000) Activity of Linezolid against gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. Journal of Antimicrob. Chemothera. 45: 797-802.
  • Ford C, Hamel J, Stapert D, Moeraman J, Huthison D, Barbachyn M, (1999) Oxazolidinones, a new class of antimicrobials. Infec. In Med. 16: 435-445.
  • Gerson LS, Kaplan SL, Bruss VL, Arellano FM, Hafkin B, Kuter DJ, (2002) Hematological effects of Linezolid: Summary of clinical experience. Antimicrob. Agents Chemother. 46: 2723-2726.
  • Haen PJ, (1995) Principles of Haematology, WCB publishers, London, PP. 454.
  • Harbarth S.; Rutschaun O.; Sudre P. Pittel D. (1998) Impact of methicillin-resistant on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch. Inter. Med. 158: 182-189.
  • Harvey J, Maso L, (1998) The use and misuse of antibiotics in agriculture. Part1. Current Usage. Published December 1998 by Soil Association, Bristol. UK.
  • Leach TS, Cammarata SK, Hempsall KA, (2000) Linezolid for the treatment of community or hospital-acquired pneumonia caused by Staphylococcus aureus results of four randomized phase III trials (Abstract) In: Abstract of the International Congress on Infectious Diseases. Buenos Aires. Argentina. April 10-13- 2000. Boston. MA: International Society for Infectious Diseases. 224.
  • Moellering RJr, (2003) Linezolid: the first Oxazolidinone antimicrobial. Ann. Of Inter. Medi. 138: 1345-142.
  • Nalini R, Ziran HB, Wagener MM, Santa ER, Yu VL, (2004) Similar hematologic effects of long-term Linezolid and Vancomycin therapy in a prospective observational study of patients with orthopaedic infections. Clinic Infect. Disea. 38: 1058-1064.
  • Neil G. Carter, (2006) Oxazolidinone diluent: Reacting for the environmental industrial copolymers limited. Wikipedia, The free encyclopedia.
  • Nicolaou KC, Tiebes J, Theodorakis EA, Rutjes FPJ, Koide K, Sato M, Untersteller E, (1994) Journal Am. Chem. Soc. 116: 9371-9372.
  • Pat O’Connor, (2006) Staphylococcus aureus infections: new challenges from an old pathogens page two. Enferm. Infect. Microbiol. Clin. 24: 182-193.
  • Pharmacia, Upjohn, (1999) Linezolid for the treatment of vancomycin-resistant enterococcal infections: a double-blinded trial comparing 600mg linezolid every 12 hours with 200mg linezolid every 12 hours: final report of the trial M/1260/0054A. Pharmacia & Upjohn study report a0052356.
  • Razonable RR, Osmon DR, Steckelberg JM, (2004) Linezolid therapy for orthopaedic infections. Mayo. Clin. Proc. 79: 1137-1144.
  • Rotti IM, (1984) Essential Immunology. 5th ed. Black Well Scientific publication, London.
  • Shinaberger DL, Marrotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, Dunyak DS, Demyan WF, Buysse JM, (1997) Mechanism of action of Oxazolidinones: effects of Linezolid and Eperizolid on translation reactions. Antimicrob. Agents Chemother. 41: 2131-2136. (Abstract).
  • Tabeekh MASA, Maktoof AR, Mohsen HAMA (2017) Solutions or alternatives to protect livestock, especially buffalo from the risk of drought in Basra Governorate. Canadian Journal of Agriculture and Crops, 2(2): 84-89.
  • Zurenko GE, Yagi HB, Schaatdt RD, Allison JW, Kilburn JO, Gilickman SE, (1996) In vitro activity of U-100592 and U- 100766, novel oxazolidinone antimicrobial agents. Antimicrob. Agents and Chemother. 40: 839-845.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.